The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT as first-line treatment for locally advanced (LA), unresectable esophageal squamous cell carcinoma (ESCC): PD-L1 tumor area positivity (TAP) score =1% subgroup analysis of RATIONALE-306.
 
Harry Yoon
Employment - Mayo Clinic
Leadership - Mayo Clinic Cancer Center
Consulting or Advisory Role - Amgen (Inst); Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; AstraZeneca; AstraZeneca (Inst); beigene; BeiGene (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Elevation Oncology; Industry Sponsor (Confidential) (Inst); Industry Sponsor (Confidential) (Inst); Jazz Pharmaceuticals (Inst); LSK Biopharma (Inst); Macrogenics (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Zymeworks (Inst)
Research Funding - Amgen (Inst); BeiGene (Inst); Bristol Myers Squibb Foundation (Inst); CARsgen Therapeutics (Inst); Merck (Inst)
Travel, Accommodations, Expenses - beigene
 
Sunnie Kim
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; BeiGene; Bristol Myers Squibb; Coherus Biosciences; Daiichi Sankyo/Lilly; Gilead Sciences; I-Mab; Jazz Pharmaceuticals; Merck
Research Funding - Merck
 
Jianming Xu
No Relationships to Disclose
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca; BeiGene; Chugai Pharma; Daiichi Sankyo/UCB Japan; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Beigene (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Bo Wei
Employment - BeOne Medicines
Stock and Other Ownership Interests - BeOne Medicines
 
Sebastian Yan
Employment - BeOne Medicines
 
Xuan Kong
No Relationships to Disclose
 
Jaffer Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Pharmaceuticals; Fresenius Kabi; Gilead Sciences; GRAIL; Lilly; Merck; Novartis; oncotherics; SERVIER; zymeworks
Consulting or Advisory Role - American Cancer Society; Amgen; Astellas Pharma; BeiGene; BeiGene; Bristol-Myers Squibb; Geneos; Gilead Sciences; Jazz Pharmaceuticals; Kyowa Kirin International; Merck; Novartis; SERVIER; Vaccinogen; Zymeworks
Research Funding - Amgen; Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; SERVIER (Inst); Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly